Takeda Pharmaceutical Co Ltd (4502.T)
20 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|76||2017||Independent Chairman of the Executive Board|
|50||2015||President, Chief Executive Officer, Representative Director|
|52||2015||Chief Medical & Scientific Officer, Director|
|58||2015||President of Japan Pharma Business Unit, Director|
- BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders
- BRIEF-Belgian Regulator FSMA Says Takeda Offer For Tigenix Priced At 1.78 Euro Per Share
- Drug company Innoviva settles with activist hedge fund Sarissa -sources
- Nikkei rises as investors chase bargains; automakers, drugmakers lead
- Nikkei rises on bargain hunting but investors edgy after wild sell-off